Cisplatin Resistance in an Ovarian Carcinoma Is Associated with a Defect in Programmed Cell Death Control Through XIAP Regulation

Oncology Research

Volumn 13, Issue 6-10, 2002, Pages 399-404

  Mansouri, Abdellah ^a   Zhan, Qingxiu ^a   Ridgway, Lon D ^a   Tian, Ling ^a   Claret, Francois Xavier ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Chemoresistance; Cisplatin; Fas L; Ovarian carcinoma; XIAP

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; CISPLATIN; FAS ANTIGEN; FAS LIGAND; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; BIRC4 PROTEIN, HUMAN; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOPROTEIN; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P53;

APOPTOSIS; CANCER CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TREATMENT PLANNING; ARTICLE; CELL CULTURE; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; OVARY TUMOR; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE GLYCOPROTEINS; OVARIAN NEOPLASMS; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 0842284092     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504003108748410     Document Type: Conference Paper

References (34)

1. Loehrer, P. J.; Einhom, L. H. Drugs five years later. Cisplatin. Annn. Intern. Med. 100:704-713; 1984.
2. Dorr, R. T.; Von Hoff, D. D. Cancer chemotherapy handbook, 2nd ed. Norwalk, CT: Appleton and Lange: 1994.
3. Ozols, R. F. Ovarian cancer, part ii: Treatment. Curr. Prob. Cancer 16:61-126; 1992.
4. Parker, R. J.; Eastman, A.; Bostick-Bruton, F.; Reed, E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. 87:772-777; 1991.
5. Makin, G.; Dive, C. Apoptosis and cancer chemotherapy. Trends Cell Biol. 11:S22-26; 2001.
6. Herr, I.; Debatin, K. M. Cellular stress response and apoptosis in cancer therapy. Blood 98:2603-2614; 2001.
7. Andrews, P. A.; Velury, S.; Mann, S. C.; Howell, S. B. Cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 48:68-73; 1988.
8. Claret, F. X.; Hibi, M.; Dhut, S.; Toda, T.; Karin, M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 383:453-457; 1996.
9. Mansouri, A.; Gaou, I.; De Kerguenec, C.; Amsellem, S.; Haouzi, D.; Berson, A.; Moreau, A.; Feldmann, G.; Letteron, P.; Pessayre, D.; Fromenty, B. An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology 117:181-190; 1999.
10. Eichhorst, S. T.; Muller, M.; Li-Weber, M.; Schulze-Bergkamen, H.; Angel, P.; Krammer, P. H. A novel ap-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol. Cell. Biol. 20:7826-7837; 2000.
11. Smith, M. L.; Fomace, A. J., Jr. Mammalian DNA damage-inducible genes associated with growth arrest and apoptosis. Mutat. Res. 340:109-124; 1996.
12. Lowe, S. W.; Ruley, H. E.; Jacks, T.; Housman, D. E. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967; 1993.
13. Ferreira, C. G.; Tolis, C.; Giaccone, G. p53 and chemosensitivity. Ann. Oncol. 10:1011-1021; 1999.
14. Waldman, T.; Kinzier, K. W.; Vogelstein, B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:5187-5190; 1995.
15. Adams, J. M.; Cory, S. The Bcl-2 protein family: Arbiters of cell survival. Science 281:1322-1326; 1998.
16. Gross, A.; McDonnell, J. M.; Korsmeyer, S. J. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1899-1911; 1999.
17. Shimizu, S.; Narita, M.; Tsujimoto, Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399:483-487; 1999.
18. Chao, D. T.; Korsmeyer, S. J. Bcl-2 family: Regulators of cell death. Annu. Rev. Immunol. 16:395-419; 1998.
19. Makin, G.; Hickman, J. A. Apoptosis and cancer chemotherapy. Cell Tissue Res. 301:143-152; 2000.
20. Johnstone, R. W.; Ruefli, A. A.; Lowe, S. W. Apoptosis: A link between cancer genetics and chemotherapy. Cell 108:153-164; 2002.
21. Kamesaki, S.; Kamesaki, H.; Jorgensen, T. J.; Tanizawa, A.; Pommier, Y.; Cossman, J. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase ii-induced DNA strand breaks and their repair. Cancer Res. 53:4251-4256; 1993.
22. Liu, J. R.; Fletcher, B.; Page, C.; Hu, C.; Nunez, G.; Baker, V. Bcl-xl is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol. Oncol. 70:398-403; 1998.
23. Clem, R. J.; Miller, L. K. Control of programmed cell death by the baculovirus genes p35 and iap. Mol. Cell. Biol. 14:5212-5222; 1994.
24. Deveraux, Q. L.; Reed, J. C. lap family proteins - suppressors of apoptosis. Genes Dev. 13:239-252; 1999.
25. LaCasse, E. C.; Baird, S.; Komeluk, R. G.; MacKenzie, A. E. The inhibitors of apoptosis (IAPS) and their emerging role in cancer. Oncogene 17:3247-3259; 1998.
26. Li, J.; Feng, Q.; Kim, J. M.; Schneiderman, D.; Liston, P.; Li, M.; Vanderhyden, B.; Faught, W.; Fung, M. F.; Senterman, M.; Komeluk, R. G.; Tsang, B. K. Human ovarian cancer and cisplatin resistance: Possible role of inhibitor of apoptosis proteins. Endocrinology 142:370-380; 2001.
27. Tang, G.; Minemoto, Y.; Dibling, B.; Purcell, N. H.; Li, Z.; Karin, M.; Lin, A. Inhibition of JNK activation through NF-kappaβ target genes. Nature 414:313-317; 2001.
28. Deveraux, Q. L.; Roy, N.; Stennicke, H. R.; Van Arsdale, T.; Zhou, Q.; Srinivasula, S. M.; Alnemri, E. S.; Salvesen, G. S.; Reed, J. C. 1APs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 17:2215-2223; 1998.
29. Friesen, C.; Herr, I.; Kranimer, P. H.; Debatin, K. M. Involvement of the CD95 (apo-1/fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2:574-577; 1996.
30. Kasibhatla, S.; Brunner, T.; Genestier, L.; Echeverri, F.; Mahboubi, A.; Green, D. R. DNA damaging agents induce expression of fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappaβ and AP-1. Mol. Cell 1:543-551; 1998.
31. Potapova, O.; Haghighi, A.; Bost, F.; Liu, C.; Birrer, M. J.; Gjerset, R.; Mercola, D. The jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J. Biol. Chem. 272:14041-14044; 1997.
32. Sanchez-Perez, I.; Murguia, J. R.; Perona, R. Cisplatin induces a persistent activation of jnk that is related to cell death. Oncogene 16: 533-540; 1998.
33. Nicholson, D. W.; Ali, A.; Thomberry, N. A.; Vaillancourt, J. P.; Ding, C. K.; Gallant, M.; Gareau, Y.; Griffin, P. R.; Labelle, M.; Lazebnik, Y. A.; et al. Identification and inhibition of the ice/ced-3 protease necessary for mammalian apoptosis. Nature 376:37-43; 1995.
34. Henkels, K. M.; Turchi, J. J. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res. 59:3077-3083; 1999.